TY - JOUR
T1 - Comorbidity between major depressive disorder and physical diseases: a comprehensive review of epidemiology, mechanisms and management
AU - Berk, Michael
AU - Köhler-Forsberg, Ole
AU - Turner, Megan
AU - Penninx, Brenda W.J.H.
AU - Wrobel, Anna
AU - Firth, Joseph
AU - Loughman, Amy
AU - Reavley, Nicola J.
AU - McGrath, John J.
AU - Momen, Natalie C.
AU - Plana-Ripoll, Oleguer
AU - O'Neil, Adrienne
AU - Siskind, Dan
AU - Williams, Lana J.
AU - Carvalho, Andre F.
AU - Schmaal, Lianne
AU - Walker, Adam J.
AU - Dean, Olivia
AU - Walder, Ken
AU - Berk, Lesley
AU - Dodd, Seetal
AU - Yung, Alison R.
AU - Marx, Wolfgang
N1 - Funding Information:
M. Berk is supported by National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship and Leadership 3 Investigator grants (nos. 1156072 and 2017131). A.J. Walker is supported by a Trisno Family Fellowship, funded in part by an NHMRC Centres of Research Excellence grant (no. 1153607); L. Schmaal by a NHMRC Leadership 1 Investigator Grant (no. 2017962); L.J. Williams by a NHMRC Emerging Leadership Fellowship (no. 1174060); W. Marx by an NHMRC Investigator Grant (no. 2008971) and a Multiple Sclerosis Research Australia early‐career fellowship; J.J. McGrath by the Danish National Research Foundation; O. Plana‐Ripoll by a Lundbeck Foundation Fellowship (no. R345‐2020‐1588) and grants from Independent Research Fund Denmark (nos. 2066‐00009B and 1030‐00085B); A. O'Neil by an NHMRC Emerging Leader 2 Fellowship (no. 2009295), and J. Firth by a UK Research and Innovation Future Leaders Fellowship (no. MR/T021780/1). Supplementary information on this study is available at https://osf.io/j53aq/?view_only=d0d1ff8d25c94ff086cc95536ff68aa6 .
Funding Information:
M. Berk is supported by National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship and Leadership 3 Investigator grants (nos. 1156072 and 2017131). A.J. Walker is supported by a Trisno Family Fellowship, funded in part by an NHMRC Centres of Research Excellence grant (no. 1153607); L. Schmaal by a NHMRC Leadership 1 Investigator Grant (no. 2017962); L.J. Williams by a NHMRC Emerging Leadership Fellowship (no. 1174060); W. Marx by an NHMRC Investigator Grant (no. 2008971) and a Multiple Sclerosis Research Australia early-career fellowship; J.J. McGrath by the Danish National Research Foundation; O. Plana-Ripoll by a Lundbeck Foundation Fellowship (no. R345-2020-1588) and grants from Independent Research Fund Denmark (nos. 2066-00009B and 1030-00085B); A. O'Neil by an NHMRC Emerging Leader 2 Fellowship (no. 2009295), and J. Firth by a UK Research and Innovation Future Leaders Fellowship (no. MR/T021780/1). Supplementary information on this study is available at https://osf.io/j53aq/?view_only=d0d1ff8d25c94ff086cc95536ff68aa6.
Publisher Copyright:
© 2023 World Psychiatric Association.
PY - 2023/10
Y1 - 2023/10
N2 - Populations with common physical diseases - such as cardiovascular diseases, cancer and neurodegenerative disorders - experience substantially higher rates of major depressive disorder (MDD) than the general population. On the other hand, people living with MDD have a greater risk for many physical diseases. This high level of comorbidity is associated with worse outcomes, reduced adherence to treatment, increased mortality, and greater health care utilization and costs. Comorbidity can also result in a range of clinical challenges, such as a more complicated therapeutic alliance, issues pertaining to adaptive health behaviors, drug-drug interactions and adverse events induced by medications used for physical and mental disorders. Potential explanations for the high prevalence of the above comorbidity involve shared genetic and biological pathways. These latter include inflammation, the gut microbiome, mitochondrial function and energy metabolism, hypothalamic-pituitary-adrenal axis dysregulation, and brain structure and function. Furthermore, MDD and physical diseases have in common several antecedents related to social factors (e.g., socioeconomic status), lifestyle variables (e.g., physical activity, diet, sleep), and stressful live events (e.g., childhood trauma). Pharmacotherapies and psychotherapies are effective treatments for comorbid MDD, and the introduction of lifestyle interventions as well as collaborative care models and digital technologies provide promising strategies for improving management. This paper aims to provide a detailed overview of the epidemiology of the comorbidity of MDD and specific physical diseases, including prevalence and bidirectional risk; of shared biological pathways potentially implicated in the pathogenesis of MDD and common physical diseases; of socio-environmental factors that serve as both shared risk and protective factors; and of management of MDD and physical diseases, including prevention and treatment. We conclude with future directions and emerging research related to optimal care of people with comorbid MDD and physical diseases.
AB - Populations with common physical diseases - such as cardiovascular diseases, cancer and neurodegenerative disorders - experience substantially higher rates of major depressive disorder (MDD) than the general population. On the other hand, people living with MDD have a greater risk for many physical diseases. This high level of comorbidity is associated with worse outcomes, reduced adherence to treatment, increased mortality, and greater health care utilization and costs. Comorbidity can also result in a range of clinical challenges, such as a more complicated therapeutic alliance, issues pertaining to adaptive health behaviors, drug-drug interactions and adverse events induced by medications used for physical and mental disorders. Potential explanations for the high prevalence of the above comorbidity involve shared genetic and biological pathways. These latter include inflammation, the gut microbiome, mitochondrial function and energy metabolism, hypothalamic-pituitary-adrenal axis dysregulation, and brain structure and function. Furthermore, MDD and physical diseases have in common several antecedents related to social factors (e.g., socioeconomic status), lifestyle variables (e.g., physical activity, diet, sleep), and stressful live events (e.g., childhood trauma). Pharmacotherapies and psychotherapies are effective treatments for comorbid MDD, and the introduction of lifestyle interventions as well as collaborative care models and digital technologies provide promising strategies for improving management. This paper aims to provide a detailed overview of the epidemiology of the comorbidity of MDD and specific physical diseases, including prevalence and bidirectional risk; of shared biological pathways potentially implicated in the pathogenesis of MDD and common physical diseases; of socio-environmental factors that serve as both shared risk and protective factors; and of management of MDD and physical diseases, including prevention and treatment. We conclude with future directions and emerging research related to optimal care of people with comorbid MDD and physical diseases.
UR - http://www.scopus.com/inward/record.url?scp=85171294939&partnerID=8YFLogxK
U2 - 10.1002/wps.21110
DO - 10.1002/wps.21110
M3 - Article
C2 - 37713568
AN - SCOPUS:85171294939
SN - 1723-8617
VL - 22
SP - 366
EP - 387
JO - World Psychiatry
JF - World Psychiatry
IS - 3
ER -